Compare SEVN & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SEVN | SGMT |
|---|---|---|
| Founded | 1986 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.9M | 676.3M |
| IPO Year | 2008 | 2021 |
| Metric | SEVN | SGMT |
|---|---|---|
| Price | $7.46 | $11.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | $10.50 | ★ $26.13 |
| AVG Volume (30 Days) | 137.1K | ★ 865.8K |
| Earning Date | 04-28-2026 | 05-14-2026 |
| Dividend Yield | ★ 13.90% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $29,383,000.00 | $2,000,000.00 |
| Revenue This Year | $27.75 | N/A |
| Revenue Next Year | $4.06 | N/A |
| P/E Ratio | $38.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.26 | $4.50 |
| 52 Week High | $10.90 | $11.45 |
| Indicator | SEVN | SGMT |
|---|---|---|
| Relative Strength Index (RSI) | 42.97 | 61.34 |
| Support Level | $7.38 | $6.60 |
| Resistance Level | $7.84 | $11.30 |
| Average True Range (ATR) | 0.12 | 0.55 |
| MACD | 0.01 | -0.07 |
| Stochastic Oscillator | 42.86 | 77.98 |
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in originating and investing in floating-rate first mortgage loans secured by middle-market and transitional commercial real estate. Its primary objective is to balance capital preservation with the generation of risk-adjusted returns. The company operates in one business segment: originating and investing in floating-rate first mortgage loans secured by CRE properties.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.